The purpose of our research is to identify potential neoantigen targets that are derived from cancer-specific splicing aberrations in pediatric brain tumors. Characterization of this novel source of neoantigens will open new opportunities for cell-based immunotherapies for pediatric brain tumor patients.
RNA-sequencing data derived from pediatric brain tumor patients in FASTQ format will be analyzed using our SNIPP platform (described in our pre-print: https://pubmed.ncbi.nlm.nih.gov/37904942/). Neojunctions identified from this data will be used to predict the corresponding neoantigen sequences.
